Status:
UNKNOWN
Human Umbilical Cord Mesenchymal Stem Cell in Cerebral Hemorrhage Sequela
Lead Sponsor:
Shenzhen Hornetcorn Bio-technology Company, LTD
Collaborating Sponsors:
Fifth Affiliated Hospital of Guangzhou Medical University
Conditions:
Cerebral Hemorrhage
Eligibility:
All Genders
40-80 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for cerebral hemorrhage sequela.
Detailed Description
Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into neural cells, which have been confirmed in in vivo and in vitro experiments. There have been few clinical report...
Eligibility Criteria
Inclusion
- Aged 40-70 intracerebral hemorrhage patient
- With stroke history of more than 3 months, less than 60 months
- National Institutes of Health stroke scale(NIHSS) score of 7 or more points
- Patient is stable (normal respiration, afebrile, BP less than mean arterial pressure of 125 mm of Hg, fasting blood sugar \<7 mg, and normal urea/electrolytes for at least 48 hours.)
Exclusion
- History of neurological disease, head injury or psychiatric disorder;
- Pregnant women;
- Impaired liver function, abnormal blood coagulation, AIDS, HIV, combine other tumor or special condition;
- Progressive apoplexy;
- With malignant tumors.
Key Trial Info
Start Date :
March 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2017
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02283879
Start Date
March 1 2015
End Date
April 1 2017
Last Update
May 24 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Fifth Affiliated Hospital Immunotherapy center
Guangzhou, Guangdong, China, 510000